D-Serine: Uses, Benefits and Considerations

1. Conditions D-Serine Has Been Studied For

D-Serine has been studied in the context of various neurological and psychiatric conditions. Research has focused on its potential role in treating schizophrenia, as well as its involvement in neurodegenerative diseases such as Alzheimer's disease. It has also been investigated for its effects on depression, anxiety, and other mood disorders, as well as cognitive enhancement in healthy individuals.

2. Efficacy in Treating Conditions

The effectiveness of D-Serine in treating conditions such as schizophrenia shows promise, as it may help alleviate some symptoms when used as an adjunct to antipsychotic medications. However, the results are mixed, and more research is needed to confirm its efficacy. In terms of neurodegenerative diseases, the evidence is still preliminary, and its clinical benefits are not clearly established.

3. Health Benefits of D-Serine

D-Serine may offer several health benefits, including:

• Enhancing cognitive function and memory
• Potentially improving symptoms of schizophrenia
• Playing a role in neuroprotection
• Modulating neurotransmitter systems, especially glutamate

4. Potential Downsides of D-Serine

While D-Serine is generally considered safe, some potential downsides include:

• Rare instances of nephrotoxicity (kidney damage)
• Possible interactions with other medications
• Uncertainty about optimal dosing and long-term safety

5. Genetic Variations and D-Serine

Genetic variations can affect how individuals metabolize and respond to D-Serine. For example, variations in the gene encoding the enzyme serine racemase, which synthesizes D-Serine in the brain, might influence the efficacy and safety profile of D-Serine supplementation. However, the research on genetic variations and their impact on D-Serine's benefits or harms is still in its infancy, and more studies are necessary to draw definitive conclusions.

Summary of Research on D-Serine

D-serine is a glia-derived neuromodulator that plays a critical role in synaptic communication in the brain. It acts as a ligand for NMDA glutamate receptors, which are essential for synaptic plasticity and involved in various neurological disorders. The synthesis, release, and clearance of D-serine at synapses are areas of active research, with implications for understanding and treating conditions such as schizophrenia and Alzheimer’s disease.

D-serine has been found to have a dual nature, being both beneficial for brain function and potentially harmful, leading to excitotoxicity. Additionally, it is synthesized by the enzyme serine racemase and broken down by D-amino acid oxidase (DAO). There is evidence that the metabolism of D-serine has evolved differently in vertebrates compared to invertebrates and may have emerged around the time arthropods diverged in evolution.

Studies on the distribution of D-serine within the mammalian brain have shown that it is concentrated in glial cells and certain neurons. Its presence in the forebrain challenges the view that glycine is the primary endogenous ligand for the glycine site of NMDA receptors. The availability of D-serine in the brain is key for the activation of synaptic NMDA receptors, as opposed to extrasynaptic receptors which prefer glycine.

Research suggests that synaptic and extrasynaptic NMDA receptors have distinct roles in brain function and pathology, with synaptic receptors relying on D-serine for processes such as learning and memory. The regulation of D-serine production and release may offer novel approaches to neuroprotection and could be used as a potential treatment for schizophrenia.

Implications for Neurological Disorders

D-serine's involvement in NMDA receptor function is significant for understanding brain development and neurotransmitter dynamics. With its importance in the pathophysiology of schizophrenia and potential impact on excitatory synaptic transmission, D-serine becomes a focal point for developing therapeutic interventions. Identifying how D-serine levels are affected in neurological diseases and how they modulate NMDA receptor activity is crucial for advancing treatment strategies.

References:

1. D-serine signalling in the brain: friend and foe
2. The N-methyl D-aspartate receptor glycine site and D-serine metabolism: an evolutionary perspective
3. Characterization of a [3H]glycine recognition site as a modulatory site of the N-methyl-D-aspartate receptor complex
4. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes
5. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses
6. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists
7. D-serine: physiology and pathology
8. Synaptic and extrasynaptic NMDA receptor NR2 subunits in cultured hippocampal neurons
9. NMDA receptor surface mobility depends on NR2A-2B subunits
10. The subtype of GluN2 C-terminal domain determines the response to excitotoxic insults
11. Immunohistochemical evidences for localization and production of D-serine in some neurons in the rat brain
12. Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine
13. Serine racemase: a glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission
14. Characterization and localization of a human serine racemase
15. Immunocytochemical analysis of D-serine distribution in the mammalian brain reveals novel anatomical compartmentalizations in glia and neurons
16. Cofactors of serine racemase that physiologically stimulate the synthesis of the N-methyl-D-aspartate (NMDA) receptor coagonist D-serine
17. Allosteric regulation of mouse brain serine racemase
18. Direct calcium binding results in activation of brain serine racemase
19. Dual substrate and reaction specificity in mouse serine racemase: identification of high-affinity dicarboxylate substrate and inhibitors and analysis of the beta-eliminase activity
20. Regulation of serine racemase activity by amino acids
21. Serine racemase: activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration
22. Mouse brain serine racemase catalyzes specific elimination of L-serine to pyruvate
23. Gene expression of D-amino acid oxidase in cultured rat astrocytes: regional and cell type specific expression
24. Characterization of human D-amino acid oxidase
25. D-amino-acid oxidase is confined to the lower brain stem and cerebellum in rat brain: regional differentiation of astrocytes
26. Immunocytochemical localization of D-amino acid oxidase in rat brain
27. Sensitive determination of D-amino acids in mammals and the effect of D-amino-acid oxidase activity on their amounts
28. D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia
29. High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia
30. A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia
31. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study
32. High dose D-serine in the treatment of schizophrenia
33. D-serine adjuvant treatment alleviates behavioural and motor symptoms in Parkinson's disease
34. Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder
35. Free D-serine concentration in normal and Alzheimer human brain
36. Presence of the N-methyl-D-aspartate-associated glycine receptor agonist, D-serine, in human temporal cortex: comparison of normal, Parkinson, and Alzheimer tissues
37. Free D-serine in post-mortem brains and spinal cords of individuals with and without neuropsychiatric diseases
38. Serine racemase modulates intracellular D-serine levels through an alpha,beta-elimination activity
39. Effects of Chronic D-Serine Elevation on Animal Models of Depression and Anxiety-Related Behavior
40. Simultaneous analysis of D- and L-serine in cerebrospinal fluid by use of HPLC
41. Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients
42. Astrocytes contain a vesicular compartment that is competent for regulated exocytosis of glutamate
43. Glutamate receptor activation triggers a calcium-dependent and SNARE protein-dependent release of the gliotransmitter D-serine
44. D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors
45. D-serine as a gliotransmitter and its roles in brain development and disease
46. Astrocytes use a novel transporter to fill gliotransmitter vesicles with D-serine: evidence for vesicular synergy
47. Immunogold detection of L-glutamate and D-serine in small synaptic-like microvesicles in adult hippocampal astrocytes
48. Neuronal release of D-serine: a physiological pathway controlling extracellular D-serine concentration
49. Neuronal D-serine and glycine release via the Asc-1 transporter regulates NMDA receptor-dependent synaptic activity
50. Astrocytes release D-serine by a large vesicle
51. TRPA1 channels are regulators of astrocyte basal calcium levels and long-term potentiation via constitutive D-serine release
52. Regulation of serine racemase activity by D-serine and nitric oxide in human glioblastoma cells
53. Mutual regulation between serine and nitric oxide metabolism in human glioblastoma cells
54. Voltage-dependent calcium channel involvement in NMDA-induced activation of NOS
55. Effects of low-dose D-serine on recognition and working memory in mice
56. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo
57. Blockade of glycine transporter-1 (GLYT-1) potentiates NMDA receptor-mediated synaptic transmission in hypoglossal motorneurons
58. The presence of free D-serine in rat brain
59. Glycine potentiates the NMDA response in cultured mouse brain neurons
60. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor
61. NMDA receptors in clinical neurology: excitatory times ahead
62. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor
63. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes
64. Glycine regulation of synaptic NMDA receptors in hippocampal neurons
65. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic
66. D-Serine differently modulates NMDA receptor function in rat CA1 hippocampal pyramidal cells and interneurons
67. Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices
68. D-serine and serine racemase are present in the vertebrate retina and contribute to the physiological activation of NMDA receptors
69. D-Serine inhibits AMPA receptor-mediated current in rat hippocampal neurons
70. Dual effect of glycine on NMDA-induced neurotoxicity in rat cortical cultures
71. Glycine transporters: essential regulators of synaptic transmission
72. Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion
73. Uptake of D- and L-serine in C6 glioma cells
74. Glial transport of the neuromodulator D-serine
75. Oxidative stress, glutamate, and neurodegenerative disorders
76. Effects of non-steroidal antiinflammatory drugs on D-serine-induced oxidative stress in vitro
77. D-serine treatment induces oxidative stress in rat brain
78. d-Serine administration provokes lipid oxidation and decreases the antioxidant defenses in rat striatum
79. Induction of cyclooxygenase-2 messenger RNA after transient and permanent middle cerebral artery occlusion in rats: comparison with c-fos messenger RNA by using in situ hybridization
80. Cyclo-oxygenase-2 messenger RNA induction in focal cerebral ischemia
81. Regional expression and role of cyclooxygenase-2 following experimental traumatic brain injury
82. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions
83. Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture
84. Molecular and cellular cognitive studies of the role of synaptic plasticity in memory
85. Genetic approaches to molecular and cellular cognition: a focus on LTP and learning and memory
86. Genetic enhancement of learning and memory in mice
87. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation
88. Glia-derived D-serine controls NMDA receptor activity and synaptic memory
89. Long-term depression: a cellular basis for learning?
90. D-serine augments NMDA-NR2B receptor-dependent hippocampal long-term depression and spatial reversal learning
91. Bell-shaped D-serine actions on hippocampal long-term depression and spatial memory retrieval
92. The effects of high Mg2+-to-Ca2+ ratios on frequency potentiation in hippocampal slices of young and aged rats
93. Impaired monosynaptic potentiation in in vitro hippocampal slices from aged, memory-deficient rats
94. Calcium homeostasis and modulation of synaptic plasticity in the aged brain
95. Expansion of the calcium hypothesis of brain aging and Alzheimer's disease: minding the store
96. Serine racemase as a prime target for age-related memory deficits
97. Reduced serine racemase expression contributes to age-related deficits in hippocampal cognitive function
98. Age-related changes in the protein expression of subunits of the NMDA receptor
99. Hippocampal dependent learning ability correlates with N-methyl-D-aspartate (NMDA) receptor levels in CA3 neurons of young and aged rats
100. The LOU/c/jall rat as an animal model of healthy aging?
101. A critical role for the glial-derived neuromodulator D-serine in the age-related deficits of cellular mechanisms of learning and memory
102. Age-related effects of the neuromodulator D-serine on neurotransmission and synaptic potentiation in the CA1 hippocampal area of the rat
103. Object location memory in mice: pharmacological validation and further evidence of hippocampal CA1 participation
104. NMDA receptor modulation by D-cycloserine promotes episodic-like memory in mice
105. Behavioral and cognitive effects of the N-methyl-D-aspartate receptor co-agonist D-serine in healthy humans: initial findings
106. Excitatory amino acids as a final common pathway for neurologic disorders
107. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease
108. Deregulation of excitatory neurotransmission underlying synapse failure in Alzheimer's disease
109. NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease
110. Aβ oligomers induce glutamate release from hippocampal neurons
111. Induction of serine racemase expression and D-serine release from microglia by secreted amyloid precursor protein (sAPP)
112. Induction of serine racemase expression and D-serine release from microglia by amyloid beta-peptide
113. D-serine and schizophrenia: an update
114. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia
115. Abnormal serine-glycine metabolism in the brains of schizophrenics
116. Abnormal serine hydroxymethyl transferase activity in the temporal lobes of schizophrenics
117. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia
118. Glycine transport inhibitors for the treatment of schizophrenia
119. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia
120. Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction
121. Pathogenic disruption of DISC1-serine racemase binding elicits schizophrenia-like behavior via D-serine depletion
122. Genetic loss of D-amino acid oxidase activity reverses schizophrenia-like phenotypes in mice
123. Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP)
125. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia
126. The glutamate receptor ion channels
127. Glutamate receptor ion channels: structure, regulation, and function
128. Pathophysiologically based treatment interventions in schizophrenia
129. Neurobiology of schizophrenia
130. D-serine added to antipsychotics for the treatment of schizophrenia
131. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia
132. D-serine added to clozapine for the treatment of schizophrenia
133. Clinical, neuropsychological, and morphometric correlates of apathy in Parkinson's disease
134. Apathy in Parkinson's disease
135. Direct and indirect presynaptic control of dopamine release by excitatory amino acids
136. Rationale for and use of NMDA receptor antagonists in Parkinson's disease
137. Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation
138. NMDA receptor regulation of memory and behavior in humans
139. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder
140. D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis
141. Paradoxical roles of serine racemase and D-serine in the G93A mSOD1 mouse model of amyotrophic lateral sclerosis
142. D-Serine Production, Degradation, and Transport in ALS: Critical Role of Methodology
143. Drug-evoked synaptic plasticity in addiction: from molecular changes to circuit remodeling
144. Synaptic plasticity and addiction
145. Cocaine self-administration selectively abolishes LTD in the core of the nucleus accumbens
146. N-Acetylcysteine reverses cocaine-induced metaplasticity
147. Reduced D-serine levels in the nucleus accumbens of cocaine-treated rats hinder the induction of NMDA receptor-dependent synaptic plasticity
148. D-serine facilitates the effects of extinction to reduce cocaine-primed reinstatement of drug-seeking behavior
149. D-serine treatment reduces cocaine-primed reinstatement in rats following extended access to cocaine self-administration
150. D-Serine facilitates the effectiveness of extinction to reduce drug-primed reinstatement of cocaine-induced conditioned place preference

Upload Whole Genome Sequencing (WGS) raw DNA data today and take a deep dive into your genome!

Or if you only have standard microarray data currently, upload raw DNA data to get started with your free DNA raw data analysis today!